Astatine-211 targets blood-borne cancers in Seattle clinical trials

[Marlin]

Astatine-211 targets blood-borne cancers in Seattle clinical trials

To deliver doses of At-211 to patients in the afternoon, scientists must begin producing At-211 in the cyclotron at midnight, bombarding a bismuth target with alpha particles from a helium source for six to seven hours. Up to 130 millicuries of At-211 are required to produce a dose of At-211.

https://www.ans.org/news/article-4305/astatine211-targets-bloodborne-cancers-in-seattle-wash-clinical-trials/